Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD80 (B7-1) and CD86 (B7-2) are type I transmembrane glycoproteins belonging to the immunoglobulin superfamily, expressed primarily on antigen-presenting cells (APCs). They provide costimulatory signals to T cells through interaction with CD28, leading to T cell activation. They also interact with CTLA-4, delivering inhibitory signals that regulate T cell responses. CD80 and CD86 play a crucial role in modulating immune responses and are targets for immunotherapy.
CD80 and CD86 bind to CD28 on T cells to provide costimulatory signals, promoting T cell activation and proliferation. They also bind to CTLA-4, delivering inhibitory signals that dampen T cell responses.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B7 Proteins: CD80 (B7-1) and CD86 (B7-2) (B7).